Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 5/2010

01-10-2010

Chronic Kidney Disease and Albuminuria in Arterial Hypertension

Authors: Giovanna Leoncini, Francesca Viazzi, Roberto Pontremoli

Published in: Current Hypertension Reports | Issue 5/2010

Login to get access

Abstract

Chronic kidney disease is a major public health problem worldwide: it is estimated that in the general population, 1 person in 10 has some degree of renal damage. Adequate blood pressure control represents the mainstay of treatment, to delay deterioration of renal function and prevent cardiovascular complications. Current evidence supports a target blood pressure value of 130/80 mm Hg or less (ie, <125/75 mm Hg) when proteinuria exceeds 1 g/L. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers represent the treatment of choice, especially in the presence of proteinuria. More complete blockade of the renin-angiotensin-aldosterone system (RAAS) has been advocated, using a combination of multiple RAAS blocker drugs or supramaximal doses to maximize renal protection. Achieving recommended blood pressure target values usually requires the use of multiple antihypertensive drugs, including diuretics and calcium channel blockers.
Literature
1.
Zhang QL, Rothenbacher D: Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008, 8:117.CrossRefPubMed
2.
Coresh J, Selvin E, Stevens LA, et al.: Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038–2047.CrossRefPubMed
3.
Keith DS, Nichols GA, Gullion CM, et al.: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659–663.CrossRefPubMed
4.
Go AS, Chertow GM, Fan D, et al.: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296–1305.CrossRefPubMed
5.
Astor BC, Hallan SI, Miller ER 3rd, et al.: Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008, 167:1226–1234.CrossRefPubMed
6.
United States Renal Data System, USRDS 2008 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
7.
Hsu CY, McCulloch CE, Darbinian J, et al.: Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005, 165:923–928.CrossRefPubMed
8.
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1–S266.
9.
Mancia G, De Backer G, Dominiczak A, et al.; ESH-ESC Task Force on the Management of Arterial Hypertension: 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007, 25:1751–1762.CrossRefPubMed
10.
Plantinga LC, Miller ER 3rd, Stevens LA, et al.; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team: Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999–2006. Hypertension 2009, 54:47–56.CrossRefPubMed
11.
Peterson JC, Adler S, Burkart JM, et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995, 123:754–762.PubMed
12.
Brantsma AH, Bakker SJ, Hillege HL, et al.; PREVEND Study Group: Cardiovascular and renal outcome in subjects with K/DOQI stage 1–3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant 2008, 23:3851–3858.CrossRefPubMed
13.
Iseki K, Kinjo K, Iseki C, Takishita S: Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004, 44:806–814.PubMed
14.
de Zeeuw D, Remuzzi G, Parving HH, et al.: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309–2320.CrossRefPubMed
15.
de Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921–927.CrossRefPubMed
16.
Eijkelkamp WB, Zhang Z, Remuzzi G, et al.: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007, 18:1540–1546.CrossRefPubMed
17.
Atkins RC, Briganti EM, Lewis JB, et al.: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005, 45:281–287.CrossRefPubMed
18.
Gaede P, Tarnow L, Vedel P, et al.: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004, 19:2784–2788.CrossRefPubMed
19.
Siragy HM, Carey RM: Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010, 31:541–550.CrossRefPubMed
20.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, et al.; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.CrossRefPubMed
21.
Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.CrossRefPubMed
22.
Huang XR, Chen WY, Truong LD, Lan HY: Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003, 14:1738–1747.CrossRefPubMed
23.
Fyhrquist F, Saijonmaa O: Renin-angiotensin system revisited. J Intern Med 2008, 264:224–236.
24.
Staessen J, Lijnen P, Fagard R, et al.: Rise in plasma concentration of aldosterone during longterm angiotensin II suppression. J Endocrinol 1981, 91:457–465.CrossRefPubMed
25.
• Kunz R, Friedrich C, Wolbers M, Mann JF: Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008, 148:30–48. This meta-analysis shows no difference between ACE inhibitors and ARBs in reducing urinary protein excretion. Proteinuria reduction is greater with dual RAAS blockade than with single-drug therapy. PubMed
26.
Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124.CrossRefPubMed
27.
The Editors of The Lancet: Retraction—Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. The Lancet 2009, 374:1226.
28.
• Mann JF, Schmieder RE, McQueen M, et al.; ONTARGET investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547–553. Renal data from the ONTARGET study demonstrated no renal benefit from dual RAAS inhibitors CrossRefPubMed
29.
Fried LF, Duckworth W, Zhang JH, et al.; VA NEPHRON-D Investigators: Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009, 4:361–368.CrossRefPubMed
30.
Wang CT, Zou LX, Navar LG: Renal responses to AT1 blockade in angiotensin II-induced hypertensive rats. J Am Soc Nephrol 1997, 8:535–542.PubMed
31.
Rakugi H, Wang DS, Dzau VJ, Pratt RE: Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994, 90:449–455.PubMed
32.
Wagner J, Gehlen F, Ciechanowicz A, Ritz E: Angiotensin II receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 1999, 10:545–551.PubMed
33.
Schmieder RE, Klingbeil AU, Fleischmann EH, et al.: Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005, 16:3038–3045.CrossRefPubMed
34.
Rossing K, Schjoedt KJ, Jensen BR, et al.: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005, 68:1190–1198.CrossRefPubMed
35.
Hollenberg NK, Parving HH, Viberti G, et al.: Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007, 25:1921–1926.CrossRefPubMed
36.
•• Burgess E, Muirhead N, Rene de Cotret P, et al.; SMART (Supra Maximal Atacand Renal Trial) Investigators: Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009, 20:893–900. Supramaximal doses of candesartan provide a greater reduction in proteinuria than conventional doses (ie, 16 mg/d) regardless of blood pressure reduction. CrossRefPubMed
37.
Hou FF, Xie D, Zhang X, et al.: Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007, 18:1889–1898.CrossRefPubMed
38.
39.
•• Parving HH, Persson F, Lewis JB, et al.; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433–2446. This study was the first demonstration of greater proteinuria reduction with the novel direct renin blocker, aliskiren, in addition to an ARB in patients with hypertension and diabetic nephropathy.CrossRefPubMed
40.
Parving HH, Brenner BM, McMurray JJ, et al.: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009, 24:1663–1671.CrossRefPubMed
41.
Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4:542–551.CrossRefPubMed
42.
Ruggenenti P, Fassi A, Ilieva AP, et al.; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004, 351:1941–1951.CrossRefPubMed
43.
de Galan BE, Perkovic V, Ninomiya T, et al.; ADVANCE Collaborative Group: Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009, 20:883–892.CrossRefPubMed
44.
Bilous R, Chaturvedi N, Sjølie AK, et al.: Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009, 151:11–20.PubMed
45.
Haller H, Viberti GC, Mimran A, et al.: Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006, 24:403–408.CrossRefPubMed
46.
Sarafidis PA, Khosla N, Bakris GL: Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007, 49:12–26.CrossRefPubMed
47.
• Bakris GL, Sarafidis PA, Weir MR, et al.; ACCOMPLISH Trial Investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375:1173–1181. This recent analysis of the ACCOMPLISH trial showed that antihypertensive combination therapy with ACE inhibitors plus calcium channel blockers is more effective than treatment with ACE inhibitors and diuretics for slowing progression of CKD.CrossRefPubMed
Metadata
Title
Chronic Kidney Disease and Albuminuria in Arterial Hypertension
Authors
Giovanna Leoncini
Francesca Viazzi
Roberto Pontremoli
Publication date
01-10-2010
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 5/2010
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-010-0141-3

Other articles of this Issue 5/2010

Current Hypertension Reports 5/2010 Go to the issue

ReviewPaper

Should All Hypertensive Dialysis Patients Receive a Blocker of the Renin-Angiotensin System?

ReviewPaper

Masked Hypertension: Evidence of the Need to Treat

ReviewPaper

Assessment of Cardiovascular Risk

Literature Alert

Prorenin: Where Does It Stand?

ReviewPaper

Hypertension in the Elderly: What Is the Goal Blood Pressure Target and How Can This Be Attained?

ReviewPaper

Does Blockade of the Renin-Angiotensin-Aldosterone System Slow Progression of All Forms of Kidney Disease?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits